Popular
MRNA · Medicine & biotech · U.S.

Moderna

Makes mRNA vaccines, including its Spikevax COVID-19 shot.

Company Health

10
/100
Fragile
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $145 of every $100 in sales.
Is it growing?
0 of 25 · Poor
Sales shrank about 53% a year over the last 3 years.
Can it handle what it owes?
10 of 25 · Okay
Its business used cash last year, and it owes $30 of every $100 it owns.
Does it bring in spare cash?
0 of 25 · Poor
It spent more cash than it brought in: $106 of every $100 in sales.

Who owns it

1 of 23 own it · 1 sold some
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Moderna’s yearly reports. Tap a year to see its figures.

Sales and profit

Sales grew from $803 million in 2020 to $1.94 billion in 2025, and it made a profit in 2 of the 6 years.
2025
Sales
$1.94 billion
Loss
$2.82 billion

Spare cash each year

It had cash to spare in 3 of the 6 years, but in 2025 it spent $2.06 billion more than it brought in.
2025
Cash shortfall
$2.06 billion
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owned $12.3 billion, including $2.60 billion in cash, and owed $3.69 billion.

Key facts

From its yearly report for 2025.
Sales
$1.94 billion
Loss
$2.82 billion
Cash shortfall
$2.06 billion
Cash in the bank
$2.60 billion
Everything it owes
$3.69 billion
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-K, filed Feb 20, 2026
Figures from Moderna’s yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy